SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

NCT06889493 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Carcinoma
Neuroendocrine Tumors

Interventions

BIOLOGICAL: Seneca Valley Virus-001 (SVV-001)
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Peter Hosein, MD

Collaborators

[object Object]